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Pitfalls in the measurement of
tissue DDAH activity: is DDAH
sensitive to nitrosative and
oxidative stress?
Kidney International (2008) 74, 969; doi:10.1038/ki.2008.360
To the Editor: Tain and Baylis1 recently reported on a
dimethylarginine dimethylaminohydrolase (DDAH) activity
assay for kidney homogenate. Using this assay, which is a
modification of the Prescott–Jones colorimetric assay,2 Tain
and Baylis1 found that nitrite, the nitric oxide (NO) donor
diethylamine NONOate and the superoxide forming agent
2,3-dimethoxy-1,4-naphthoquinone inhibited (at 0.1 and
1 mM) cortical DDAH activity in vitro.1 In our opinion, this
work does not provide evidence of DDAH sensitivity to NO
and oxidative stress because of methodological problems
which we would like to discuss here.
The inhibition of DDAH activity by nitrite1 is very
surprising. A possible explanation for the apparent inhibitory
effect of nitrite and diethylamine NONOate could be
interference by these species and nitrate in the DDAH assay,
for example at the derivatization step. Indeed, Prescott and
Jones2 reported that nitrate inhibited color development in
their assay. We are unaware of interference studies by the
substances tested in the paper by Tain and Baylis.1 That
diethylamine NONOate was less effective than nitrite,1 argues
against a sensitivity of DDAH activity to nitrosative stress. In
addition, inhibition of DDAH activity seen by nitrite and the
NO donor diethylamine NONOate1 could have resulted from
artifactual S-nitrosation of DDAH SH-groups by nitrous acid
(pKa 3.4). Using a fully validated and interference-free gas
chromatography–mass spectrometry assay,3 we found no
inhibition of DDAH activity by nitrite or nitrate in vivo in
humans3 and in vitro (Figure 1).
Like N-ethylmaleimide,4 2,3-dimethoxy-1,4-naphthoqui-
none is a potent SH-groups alkylating agent. The inhibitory
effect of 2,3-dimethoxy-1,4-naphthoquinone on DDAH
activity1 could have resulted from the ability of 2,3-
dimethoxy-1,4-naphthoquinone to alkylate rather than to
oxidize SH-groups of DDAH.
Albeit generally accepted, there is no solid evidence of
the sensitivity of DDAH to nitrosative and oxidative stress
in vitro and in vivo. Investigations addressing this issue
should: (1) avoid potential methodological pitfalls; (2)
involve use of specific superoxide-producing agents or
enzymes; and (3) last but not least important, involve use
of drugs at (patho)physiologically or pharmacologically
relevant concentrations.
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Response to ‘Pitfalls in the
measurement of tissue DDAH
activity: is DDAH sensitive to
nitrosative and oxidative stress?’
Kidney International (2008) 74, 969–970; doi:10.1038/ki.2008.370
We have the following responses to the comments made by
Dr Chobanyan and Dr Tsikas, regarding the quality of our
recent publication ‘Determination of dimethylarginine
dimethylaminohydrolase [DDAH] activity in the kidney’.1
Nitrite is a source of nitric oxide synthase-independent
nitric oxide production under hypoxic and normoxic
conditions2,3 and that was the reason we used nitrite in
these studies. Regarding possible background effects of
nitrite (and any other agent that we used), every reagent in
our assay was run with a corresponding blank (that is
asymmetric dimethylarginine (ADMA) omitted) see sup-
plement, published online.1 Neither nitrite nor diethyl-
amine NONOate had any effect on the blank value,
demonstrating that the decrease of color formation by
nitrite is not due to interference. The lack of an effect of
nitric oxide on DDAH activity in the study by Tsikas and
co-workers4 may be related to their use of a different tissue
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Figure 1 | Effect of sodium nitrite and nitrate on DDAH activity
in vitro in rat liver homogenate (0.1 M phosphate buffer, pH
7.2). DDAH activity was determined by measuring dimethylamine
(DMA) formation from ADMA (100 mM) by GC–MS.3 Data are
presented as mean±standard deviation from triplicate
incubations. DDAH activity of 100% corresponds to
17.8±1.7 pmol DMA per minmg protein. Nitrite and nitrate
(0–1 mM) did not interfere with the GC–MS measurement of DMA
in rat liver homogenate in the absence of ADMA (data not shown).
Kidney International (2008) 74, 962–973 969
(liver) and/or different nitric oxide donors/doses, and/or
may reflect inherent problems with the assumption that
the gas chromatography–mass spectrometry assay of
dimethylamine (DMA) formation gives a direct measure
of ADMA breakdown (see below). We did find that nitrate
reduced color formation in our DDAH assay (unpublished)
as also reported by Prescott and Jones;5 however, we did
not add nitrate to the assay in our study.1
We agree that 2,3 dimethoxy-1,4-napthoquinone may
have other actions in addition to generation of superoxide.
It would be interesting to see a comparison between
different oxidizing agents, however, Tsikas and co-workers4
do not assess the impact of 2,3 dimethoxy-1,4-napthoqui-
none (or other superoxide generators) using their gas
chromatography–mass spectrometry assay.
Dr Tsikas and Dr Chobanyan suggest that their DMA
production assay provides a definitive DDAH activity
assay, but lacking is any direct evidence that 1 U of DMA
produced¼ 1 U of ADMA consumed under any experi-
mental conditions. The wide range in reported urinary
DMA:ADMA ratios could reflect alterations in ADMA
synthesis, and/or DMA production through other path-
ways, and/or different handling of DMA and ADMA in
specific nephron segments as well as differences in the
proportion of urinary ADMA excretion vs DDAH meta-
bolism of ADMA. In fact, although a promising tool for
study of ADMA metabolism, DMA production rate, like
citrulline production rate, provides only a surrogate
measure of ADMA breakdown and requires validation
against the ‘gold standard’ of ADMA degradation in every
in vivo and in vitro experimental condition.
Although we disagree with the criticisms of Dr
Chobanyan and Dr Tsikas regarding the quality of our
study, we are in agreement that the question of impact of
oxidative stress on DDAH activity remains to be resolved.
Indeed, we recently reported that whereas vitamin E
supplementation was successful in reducing renal cortical
oxidative stress (as measured by reduced nicotinamide
adenine dinucleotide phosphate oxidase-dependent super-
oxide production), renal DDAH activity and plasma
ADMA level was not altered in a rat model of kidney
disease.6 As Dr Vaziri points out, oxidative stress is
extremely heterogenous, may originate from many loca-
tions and in response to many different stimuli.7 It is
possible, therefore, that not all ‘oxidative stress’ is the same
in terms of impact on ADMA levels.
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Does pioglitazone provide a
better renoprotective effect than
insulin in diabetic patients?
Kidney International (2008) 74, 970–971; doi:10.1038/ki.2008.371
To the Editor: In a recent issue of Kidney International,
Ohtomo et al.1 showed that pioglitazone (PGZ), one of these
currently used thiazolidinediones, could provide better
renoprotection than insulin in an obese, hypertensive, type
2 diabetes mellitus rat model. However, a few questions
should be considered for this animal study. First, many
diabetic patients have insulin as their main treatment for
glycemic control, as the author proved PGZ has better
renoprotection, would combination treatment with insulin
and PGZ be a better regimen for diabetic patients? If the
answer is yes, why didn’t the author add another group
treated by both insulin and PGZ in their study design.
Second, the glycemic control was not better in rats treated
with PGZ than those with insulin. Is it possible that the dose
of PGZ was too low to achieve a better glycemic status?
Third, how could we explain the finding that insulin had a
renoprotective effect in the first 8 weeks but it increased urine
protein later gradually? According to Schena and Gesualdo,2
insulin can reduce oxidative stress with prevention of
accumulation of toxic advanced glycation end products,
which may provide renoprotection in the first 8 weeks.
However, in the later period, insulin may induce production
of matrix proliferation and results in glomerular sclerosis,
thus renal function may decline with increased urine protein
excretion.
Finally, the authors only provided a comparison of
clearance of creatinine in each group at 26 weeks. I would
like to have a look at the change of clearance of creatinine in
each group in a time-course manner. There might be an
initial increase of clearance of creatinine in the first 8 weeks
but with a subsequent decrease of it in insulin treated
diabetic rats. This might provide some evidence for
combination treatment with both insulin and PGZ because
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